Tamoxifen and the endometrium: Review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology

International Journal of Gynecological Pathology

Volumn 18, Issue 2, 1999, Pages 130-137

  Kennedy, Margaret M ^a,b   Baigrie, Carolyn F ^a   Manek, Sanjiv ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Endometrium; Hormone replacement therapy; Morphology; Polyp; Tamoxifen

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER RISK; DRUG EFFECT; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

EID: 0033026590     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199904000-00006     Document Type: Article

References (32)

1. Loret de Mola JR. Endometrial changes with chronic tamoxifen use. Curr Opin Obstet Gynecol 1997;9:160-4.
2. Rea D, Poole C, Gray R. Adjuvant tamoxifen: how long before we know how long? Br Med J 1998;316:1518-9.
3. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827-33.
4. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-4.
5. Cohen I, Rosen DJD, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994;52:185-90.
6. Cheng W-F, Lin H-H, Torng P-L, Huang S-C. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gvnecol Oncol 1997;66:233-7.
7. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Tamoxifen and the uterus and endometrium. Lancet 1989;1:375.
8. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-21.
9. Dallenbach-Hellweg G, Hahn U. Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (Tamoxifen) and gestagens. Int J Gynecol Pathol 1995;14:7-15.
10. Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barron B, Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125-31.
11. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, LiVolsi VA. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992;79: 111-6.
12. Berezowsky J, Chalvardjian A, Murray D. Iatrogenic endometrial megapolyps in women with breast carcinoma. Obstet Gynecol 1994;84:727-30.
13. McGonigle KF, Lantry SA, Odom-Maryon TL, Chai A, Vasilev SA, Simpson JF. Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. Cancer Lett 1996;101:59-66.
14. Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, Barakat RR. Endometrial thickness in Tamoxifen-treated patients: correlation with clinical and pathologic findings. Am J Roentgenol 1997;168: 657-61.
15. Silva EG, Tornos CS, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 1994;13:248-58.
16. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant Tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20.
17. Cohen I, Altaras MM, Shapira J, et al. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol 1996; 15:152-7.
18. Cohen CJ. Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Semin Oncol 1997;24(Suppl 1):S1-55-S1-64.
19. Clement PB, Oliva E, Young RH. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol 1996;15:222-9.
20. Peterson WF, Novak ER. Endometrial polyps. Obstet Gynecol 1956;8:40-9.
21. Schlaen I, Bergeron C, Ferenczy A, Wong P, Naves A, Bertoli R. Endometrial polyps: a study of 204 cases. Surg Pathol 1988;1: 375-82.
22. Deligdisch L. Effects of hormone therapy on the endometrium. Mod Pathol 1993;6:94-106.
23. Hendrickson MR, Kempson RL. Endometrial epithelial metaplasias: proliferations frequently misdiagnosed as adenocarcinoma: report of 89 cases and proposed classification. Am J Surg Pathol 1980;4:525-42.
24. Ismail SM. The effects of Tamoxifen on the uterus. Curr Opin Obstet Gynecol 1996;8:27-31.
25. Greeley C, Schroeder S, Silverberg SG. Microglandular hyperplasia of the cervix: a true "pill" lesion? Int J Gynecol Pathol 1995; 14:50-4.
26. Schwartz LB, Krey L, Demopoulos R, Goldstein SR, Nachtigall LE, Mittal K. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am J Obstet Gynecol 1997;176: 129-37.
27. Cohen I, Figer A, Altaras MM, et al. Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestogens. Int J Gynecol Pathol 1996;15: 17-22.
28. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164-8.
29. Wahlstrom T, Lindgren J, Korhonen M, Seppala M. Distinction between endocervical and endometrial adenocarcinoma with immunoperoxidase staining of carcinoembryonic antigen in routine histological tissue specimens. Lancet 1979;11:1159-60.
30. Nogales FF, Carvia R, Tamoxifen effects [Letter]. Am J Surg Pathol 1998;22:907.
31. Clarke MR. Uterine malignant mixed mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer. Gynecol Oncol 1993;51:411-5.
32. Sasco AJ, Raffi F, Satge D, Goburdhun J, Fallouh B, Leduc B. Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int J Gynaecol Obstet 1995;48:307-10.